MEDICAL POLICY
No. 91314-R11

ELECTROPHYSIOLOGY TESTING & CATHETER ABLATION
FOR CARDIAC ARRHYTHMIAS

Effective Date: February 1, 2017
Review Dates: 1/93, 12/99, 12/01, 12/02, 2/03, 1/04,
3/04, 3/05, 2/06, 8/06, 2/07, 4/07, 4/08, 4/09, 4/10,
4/11, 4/12, 4/13, 5/14, 5/15, 5/16, 5/17, 5/18, 11/18
Date of Origin: November 12, 1992
Status: Current

Summary of Changes

Clarifications:

- Pg. 2, Section IV. DESCRIPTION: Clarified that the Maze procedure can, in addition to being performed as an open procedure, be performed endoscopically. Also enhanced description of the convergent procedure which incorporates epicardial and endocardial ablation.

I. POLICY/Criteria

A. Electrophysiology (EP) testing does not require prior authorization.

B. Catheter ablation for cardiac arrhythmias is a covered benefit according to InterQual® criteria.

C. High-intensity focused ultrasound (HIFU), (e.g. the Epicor™ system) as a stand-alone ablative procedure for atrial fibrillation is considered investigational and is not a covered benefit. The Epicor™ procedure was reviewed by Priority Health’s Technology Assessment Committee in June 2006 and this policy reflects the recommendations of the committee.

II. MEDICAL NECESSITY REVIEW

☑ Required ☐ Not Required ☐ Not Applicable

III. APPLICATION TO PRODUCTS

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

- HMO/EPO: This policy applies to insured HMO/EPO plans.
- POS: This policy applies to insured POS plans.
- PPO: This policy applies to insured PPO plans.
- ASO: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
IV. DESCRIPTION

Atrial fibrillation (AF) is the most commonly diagnosed cardiac rhythm disturbance, with an incidence of 0.4% in the general population. AF occurs in a high percentage of patients with mitral valve (MV) disease, although it can also occur in individuals with no associated cardiac abnormalities. It is characterized by loss of normal sinoatrial electrical signal and rapid, fine, uncoordinated contraction of the atria.

Atrial fibrillation is associated with morbidity and mortality despite therapy with current antiarrhythmic drugs. Even the best available medical therapy only yields a 50-60 percent annual success rate in maintaining sinus rhythm. Side effects of these drugs can be problematic. Catheter ablation of arrhythmogenic foci can be performed using radiofrequency, microwave, and cryotherapy or ultrasound technology. The Cox-maze IV, sometimes called a mini-maze, is a closed chest, minimally-invasive endoscopic procedure that creates epicardial scar lines or lesions on the epicardium (the outside of the heart) that work to divert the abnormal electrical impulses in the heart. (The Cox-maze III is an open approach typically utilized only in conjunction with valve repair or replacement.) In the convergent procedure, upon completion of a Cox-maze IV, endocardial ablation is performed, creating any additional necessary lesions on the interior walls of the heart. High-intensity focused ultrasound (HIFU), the Epicor™ system, may also be used for ablation in conjunction with other open heart procedures.

Initial experience with catheter ablation procedures based on a creation of linear lesions in both atria was disappointing but led to the key observation that focal triggers localized in the pulmonary veins were responsible for initiation of atrial fibrillation and are thus suitable targets for catheter ablation.
Electrical isolation of all four pulmonary veins from the left atrium provides the highest cure rates for atrial fibrillation. However, the procedure is operator dependent and is associated with a small but significant risk of pulmonary vein stenosis. Given the complexity and difficulties in ablating multiple pulmonary veins, **ablation of atrial fibrillation is not considered the initial treatment of choice or the standard of care for the treatment of atrial fibrillation.**

The optimal treatment method for patients who have idiopathic paroxysmal fibrillation appears to be left atrial catheter ablation as opposed to segmental ostial catheter ablation. Patients with chronic or persistent atrial fibrillation and patients with vago-tonic type of paroxysmal atrial fibrillation pulmonary vein isolation have a low success rate. In these subgroups and in patients with paroxysmal atrial fibrillation that does not respond to pulmonary vein isolation, an approach that involves ablation within the left atrium, it is likely but not proven to yield better results.

**Future Studies:**

It is expected that with further advances in technology and simplification of techniques, radio frequency ablation of atrial fibrillation will become a widespread procedure. Methods to reduce the risk of pulmonary veins stenosis are under development. These technological developments primarily focus on design of the catheter tip, including diameter of the catheter tip and method for delivering ablative energy. Balloon-based, ultra-sound catheters using laser and cryoablation are currently being designed, as are circular catheters through which either radiofrequency or cryo lesions can be delivered.

V. CODING INFORMATION

**ICD-10 Codes** that may apply:

- **I44.30 – I44.7** Other and unspecified atrioventricular block
- **I45.0 – I45.9** Other conduction disorders
- **I46.2** Cardiac arrest due to underlying cardiac condition
- **I46.9** Cardiac arrest, cause unspecified
- **I47.0 – I47.9** Paroxysmal tachycardia
- **I48.0 – I48.92** Atrial fibrillation and flutter
- **I49.0 – I49.9** Other cardiac arrhythmias
- **I97.190 – I97.191** Other postprocedural cardiac functional disturbances following surgery
- **I97.790 – I97.791** Other intraoperative cardiac functional disturbances during surgery
CPT/HCPCS Codes

93650 Intracardiac catheter ablation of atrioventricular node function, atrioventricular conduction for creation of complete heart block, with or without temporary pacemaker placement

93653 Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording, His recording with intracardiac catheter ablation of arrhythmogenic focus, with treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or other single atrial focus or source of atrial re-entry

93654 Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording, His recording with intracardiac catheter ablation of arrhythmogenic focus; with treatment of ventricular tachycardia or focus of ventricular ectopy including intracardiac electrophysiologic 3D mapping, when performed, and left ventricular pacing and recording, when performed

93656 Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with atrial recording and pacing, when possible, right ventricular pacing and recording. His bundle recording with intracardiac catheter ablation of arrhythmogenic focus, with treatment of atrial fibrillation by ablation by pulmonary vein isolation

93655 Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary procedure)

93657 Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)

93613 Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)

33265 Endoscopy, surgical; operative tissue ablation and reconstruction of atria, limited (e.g., modified maze procedure), without cardiopulmonary bypass. (No PA required)

33266 Endoscopy, surgical; operative tissue ablation and reconstruction of atria, extensive (e.g., maze procedure), without cardiopulmonary bypass (No PA required)

Not Covered

93799 Unlisted cardiovascular service or procedure
(Not covered when used for High-intensity focused ultrasound (HIFU) ablation. Explanatory notes must accompany claim)
Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (MR) guidance

VI. REFERENCES


“Catheter Ablation of Arrhythmogenic Foci”, Blue Cross Blue Shield of Massachusetts, No: 123, 05/06. 


Microwave Surgical Ablation System for Treatment of Atrial Fibrillation, Hayes Brief, July 17, 2005.


Guidant Microwave Ablation System, Hayes Search & Summary March 30, 2005

Radiofrequency Ablation (Isolation) of the Pulmonary Veins for the Treatment of Atrial Fibrillation, Hayes Search & Summary, June 2, 2006.


Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

High Intensity Focused Ultrasound (HIFU), Cigna Medical Coverage Policy, @

AMA CPT Copyright Statement:
All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member’s plan in effect as of the date services are rendered. Priority Health’s medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health’s medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan’s ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name “Priority Health” and the term “plan” mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.